Company Events - Today s Events | 25 June 2021 stockmarketwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stockmarketwire.com Daily Mail and Mail on Sunday newspapers.
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
Tiziana Life Sciences is advancing three candidates for a variety of indications in autoimmune disease, cancer and coronavirus (COVID-19) Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis (SPMS) in a trial using nasally administered Foralumab - its fully-human anti-CD3 monoclonal antibody
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR share, compared to a current price of US$2.37.
25 May 2021 | 09:51am
StockMarketWire.com - Inflammatory diseases and cancer focused Tiziana Life Sciences said the first patient with secondary progressive multiple sclerosis was dosed in a treatment trial.
The trial was testing nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women s Hospital, Harvard Medical School, Boston, MA.
This clinical study would continue for six months to evaluate routine safety, tolerability, and neurological behaviours.
It also would examine microglial activation, immunological and neurodegenerative markers to assess clinical responses following the treatment regimen.
At 9:51am: [LON:TILS] Tiziana Life Sciences Plc share price was 0p at 92p